Pharma Research (214450) 1Q26 Earnings Review and Valuation Analysis
Pharma Research is an integrated aesthetics company operating across polynucleotide (PN)-based medical devices, cosmetics, and pharmaceuticals. In 1Q26, the company posted record quarterly revenue of KRW 146.1B (≈$96.1M) (+25% YoY) and operating income of KRW 57.3B (≈$37.7M) (+28% YoY). While the cosmetics segment drove overall growth, the pace of recovery in export medical devices has emerged as a key variable for the second half.
1. Company Overview and Core Business
Pharma Research (214450) is a KOSDAQ-listed healthcare company engaged in PN (polynucleotide)-based skin booster medical devices, cosmetics, and pharmaceuticals. The company delivered full-year 2025 revenue of 5,363억원 (≈$352.6M, +53% YoY) and operating profit of 2,144억원 (≈$141.0M, +70% YoY), sustaining strong high-growth momentum. As of Q1 2026, revenue breakdown was medical devices at 795억원 (≈$52.3M, 54%), cosmetics at 422억원 (≈$27.7M, 29%), pharmaceuticals at 214억원 (≈$14.1M, 15%), and other, with the export share expanding to 40% of total revenue (588억원, ≈$38.7M). The company has 11,565,295 shares outstanding, with a market capitalization of approximately 3조 5,274억원 (≈$2.3B).
📌 Q1 2026 export revenue of 588억원 (≈$38.7M, +30% YoY); export share expanded to 40% of total revenue
2. Core Product Competitive Analysis
Rejuran is a patented PN-based skin booster medical device and the cornerstone of domestic medical device revenue. Q1 2026 domestic medical device revenue of 584억원 (≈$38.4M) represents an all-time quarterly high once adjusted for the net-basis reclassification of marketing cost-sharing fees (approximately 12억원 (≈$0.8M) deduction effect). Cosmetics revenue of 422억원 (≈$27.7M) grew +51% YoY, underpinned by placements in 380 U.S. Sephora stores and approximately 300 Sephora locations in China. Europe's share of medical device export revenue expanded from 20% in Q1 2025 to 35% in Q1 2026, reflecting active export market diversification. An EBD device is scheduled for H2 2026, with a collagen skin booster planned for 2027.*1
| Category | Details |
|---|---|
| Positioning | In-house PN-based skin booster raw material; leading aesthetics medical device brand in Korea |
| Competitive Advantages | Sustained high-margin structure with GPM 77% and OPM 39%; direct brick-and-mortar placement at Sephora |
| Competitive Disadvantages | QoQ volatility in export medical device sales due to delayed reorders from Japan and deceleration in China |
3. Valuation Analysis
As of the closing price of KRW 305,000 (≈$200.5) on May 21, 2026, Trailing PER stands at 21.5x (Naver Finance), Forward PER at 16.0x, and PBR at 5.12x. Starting from 2025A operating income of KRW 214.4B (≈$141.0M) and controlling net income of KRW 165.1B (≈$108.5M), achieving 2026F operating income of KRW 258.0B (≈$169.6M)*2 and controlling net income of KRW 195.0B (≈$128.2M)*2 would trigger automatic Forward PER compression in tandem with earnings growth. PBR of 5.12x relative to 2026F ROE of 25.5%*2 is at a level that warrants capital efficiency review in the context of profitability; net debt of -KRW 402.3B (≈-$264.5M) (net cash) as of 2025A confirms continued financial soundness.
📌 Trailing 21.5x → Forward 16.0x: Valuation compression structure if 2026F earnings growth is realized
| Metric | Current | Sector Average | Interpretation |
|---|---|---|---|
| Trailing PER | 21.5x | N/A | Based on 2025 actual results |
| Forward PER | 16.0x | N/A | Automatic compression structure upon 2026F earnings growth*2 |
| PBR | 5.12x | N/A | Reflects high-ROE (25.5%) sector characteristics |
| OPM | 39.2% | N/A | Confirms sustained high-margin structure in 1Q26 |
4. Risks & Monitoring Points
The top monitoring priority is whether export medical device revenue recovers on a quarterly basis. Export medical device revenue in 1Q26 was KRW 21.1B (≈$13.9M), down QoQ -10% due to delayed Japanese re-orders and a slowdown in China. Increased SG&A from expanded Rejuran outdoor advertising may limit further OPM leverage, and changes in inbound foreign visitor counts (1Q26: 4.74M visitors, QoQ -2.3%) show correlation with domestic medical device revenue.
- ⚠️ Risk of delayed export recovery if slowdowns in export medical device markets (Japan·China) persist
- ⚠️ Potential cap on additional OPM leverage due to rising marketing costs (outdoor advertising and channel expansion)
- ⚠️ Volatility in domestic medical device revenue linked to declining inbound foreign visitor traffic
- 📌 2Q26 export medical device revenue (QoQ recovery vs. KRW 21.1B (≈$13.9M) in the prior quarter; Europe shipment volumes)
- 📌 Whether quarterly GPM remains ≥75% and OPM remains ≥38%
- 📌 Monthly inbound foreign visitor traffic (leading indicator for domestic medical device revenue)
5. Recent DART Filings
As of the analysis date (2026-05-23), no DART regulatory filings with high relevance to this report have been identified.
Pharma Research sustained high growth in its cosmetics segment (+51% YoY) and a high-margin structure (OPM 39.2%) in 1Q26. The Forward PER of 16.0x represents a compressed multiple relative to Trailing, already pricing in earnings growth. The pace of export medical device recovery and the magnitude of SG&A increases are expected to serve as critical inflection points for full-year 2026 performance.
📎 References & Estimation Basis
- *1 The 2H 2026 EBD device and 2027 collagen skin booster launch schedules are based on company guidance as disclosed in Yuanta Securities and Daishin Securities reports dated May 11, 2026, and are subject to change depending on regulatory approval and mass production timelines.
- *2 The 2026F operating income of KRW 258B (≈$169.6M), net profit attributable to controlling shareholders of KRW 195B (≈$128.2M), and ROE of 25.5% are based on Yuanta Securities estimates as of May 11, 2026. Daishin Securities, as of the same date, estimated operating income of KRW 283B (≈$186.1M) and EPS of KRW 21,831 (≈$14.4), reflecting divergence in consensus estimates across brokerages.
- *3 USD equivalents (≈$) are approximate, calculated at 1 USD = 1,521 KRW (as of 2026-05-23, source: Yahoo Finance).
본 보고서는 정보 제공 목적이며 투자 권유가 아닙니다. 투자 결정은 본인 책임입니다.
댓글 없음:
댓글 쓰기